28th Jul 2022 12:03
GSK PLC - London-based pharmaceutical firm - Signs a framework contract with the European Commission's Health Emergency Preparedness & Response Authority. Says contract is for the reservation of future production and supply of 85 million doses of its influenza vaccine Adjupanrix. Does not disclose the financial details of the contract.
Influenza, commonly called the flu, is a viral infection that attacks the respiratory system, which includes the nose, throat and lungs.
"This agreement with Hera concludes a series of contracts secured by GSK this year, under which it could provide at least 200 million doses of pandemic influenza vaccine to governments around the world," President of Vaccines & Global Health Roger Connor says.
Current stock price: 1,744.80 pence
12-month change: up 23%
By Abby Amoakuh; [email protected]
Copyright 2022 Alliance News Limited. All Rights Reserved.
Related Shares:
Glaxosmithkline